Single Muscle Immobilization Decreases Single-Fibre Myosin Heavy Chain Polymorphism: Possible Involvement of p38 and JNK MAP Kinases by Frédéric Derbré (3157917)

“…</p><p>Conclusions</p><p>Single muscle immobilization at neutral length induces a shift of MHC composition toward a faster contractile phenotype and decreases the polymorphic profile of single fibres. …”

S2 Data - by Nancy Fullman (243628)

“…For diabetes, HealthRise was associated with A1c decreases in Ramsey (1.3 [0.4–2.2]). Qualitative data showed the value of home visits alongside clinic-based services; however, challenges remained, including community health worker retention and program sustainability.…”

Engagement of monocytes, NK cells, and CD4⁺ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV_mac251 vaginal acquisition by Giacomo Gorini (5693312)

“…Using the systems biology approach, we demonstrate that specific expression profiles of plasmablasts, NKG2A⁺ cells, and monocytes elicited by the ALVAC-based regimen correlated with decreased risk of virus acquisition.…”

Overview of study procedures. by Matthew G. Vinson (22593374)

“…VIDEO and CONTROL were associated with a similar rise in intent to decrease OTC NSAID use (1.92 (SD: 4.41) vs. 1.36 (SD: 3.46), p = 0.150) and a similar decrease in NSAIDs exposure (−32.8% in VIDEO and −36.5% in CONTROL, p = 0.520) 4 weeks post-intervention. …”

Meltrin β does not affect the expression of EphA4 on the cell surface nor the initial association between ephrin-A5 and EphA4, but decreases accessibility of antibodies that recognize the EphA4 C-terminus. by Norihiro Yumoto (270290)

Subjects:

S5 Fig - by Jordan K. Abbott (8934239)

Magnification X2 of Fig 4A. by Huan W. Yang (19746645)

“…<i>intracellularis</i> bacterial load peaks at 5 dpi. The induction of pro-inflammatory cytokines expression is consistent with the decreased viability of <i>L</i>. …”

Inhibition of G9a decreases the tumorigenicity of neuroblastoma cells. by Xiao-Xue Ke (626989)

Propensity-score matched open aortic group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

Pre-match open aortic group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

Pre-match CABG/Valve group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

Propensity-score matched CABG/Valve group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER. by Charlotte J. van Ginkel (20790466)

“…<p>(A) A steady increase in TEER is seen in differentiated porcine urothelial cells, corresponding with a tight epithelium and reaching the upper reliable limit of the equipment (3300 Ω cm²) around day 35. …”

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)